Form 4: Arcus Biosciences General Counsel Receives Stock Options and Restricted Stock Units

Arcus Biosciences' General Counsel, Carolyn C. Tang, was granted 150,000 stock options and 37,000 restricted stock units on January 23, 2025.

Summary

• Carolyn C. Tang, General Counsel of Arcus Biosciences, received 150,000 stock options with an exercise price of $13.33 on January 23, 2025.
• These options become exercisable in 48 equal monthly installments starting after January 1, 2025, contingent on her continued service to the company.
• Ms. Tang also received 37,000 restricted stock units on the same date.
• These restricted stock units vest in four equal annual installments beginning December 15, 2025, also subject to her continued service.
• Following these transactions, Ms. Tang directly owns 137,623 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The grant of stock options and restricted stock units aligns the General Counsel's interests with those of the shareholders.
• The vesting schedules for both the options and restricted stock units encourage long-term commitment from the General Counsel.

Risks

• The value of the stock options and restricted stock units is dependent on the future performance of Arcus Biosciences' stock price.
• The vesting of the options and restricted stock units is contingent on the General Counsel's continued employment with the company.

Future Outlook

The document does not contain any forward-looking statements about the company's future performance, but it does outline the vesting schedule for the granted equity.

Industry Context

The granting of stock options and restricted stock units is a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants and restricted stock units are standard compensation practices for executives in publicly traded biotech companies.
• The vesting schedules described are typical, with monthly vesting for options and annual vesting for restricted stock units.
• Companies like Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN) also use similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize the General Counsel to contribute to the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, insider trading, executive compensation, Arcus Biosciences, RCUS, Carolyn C. Tang, General Counsel